The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy

Neuroendocrinology Letters

Volumn 28, Issue 1, 2007, Pages 45-51

  Heracek, Jiri ^a   Urban, Michael ^a   Sachova, Jana ^a   Kuncova, Jitka ^b   Eis, Vaclav ^a   Mandys, Vaclav ^a   Hampl, Richard ^c   Starka, Luboslav ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF PISA   (Italy)

^c INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Androgens; Estrogens; Follicle stimulating hormone; Gleason score; Luteinizing hormone; Prolactin; Prostate cancer; Prostate specific antigen; Radical prostatectomy; Testosterone

Indexed keywords

ESTRADIOL; FOLLITROPIN; HYDROCORTISONE; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOCRINOLOGY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

EID: 33847163949     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ben-Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol. 1999; 161: 970-6.
2. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997; 33: 1075-1107.
3. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002; 38: 99-166.
4. Crabb JW, Armes LG, Carr SA, Johnson CM, Roberts GD, Bordoli RS, et al. Complete primary structure of prostatropin, a prostate epithelial cell growth factor. Biochemistry. 1986; 25: 4988-93.
5. Di Saint Agnese PA, deMesey Jensen KL. Somatostatin and/or somatostatin like immunoreactive endocrine/paracrine cells in the human prostate gland. Arch Pathol Lab Med. 1984; 108: 693-6.
6. Dowling CR, Risbridger GP. The role of inhibins and activins in prostate cancer pathogenesis. Endocr Relat Cancer. 2000; 7: 243-56.
7. Eble JN, Kauter G, Epstein JI, Sesterhenn I. Pathology and genetics of tumours of the urinary system and male genital organs (IARC/World Health Organization Classification of Tumours). Lyon, France: IARC Press; 2003.
8. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) Consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005; 29: 1228-42.
9. Farnsworth WE. A proposed physiological role of prostaglandin F2 alpha in prostatic function. Prog Clin Biol Res. 1981; 75A: 225-30.
10. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996; 88: 1118-26.
11. Garde SV, Sheth AR, Shah MG, Kulkarni SA. Prostate - an extrapituitary source of follicle-stimulating hormone (FSH): occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents. Prostate. 1991; 18: 271-87.
12. Hall GS, Kramer CE, Epstein JI. Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol. 1992; 16: 315-24.
13. Hampl R. Comparison of three immunoassays for testosterone determination. In: Görög S, editor. Advances in Steroid Analysis '93. Budapest: Akadémiai Kiadó 1994.163-9.
14. Harper GP, Barde YA, Burnstock G, Carstairs JR, Dennison ME, Suda K, et al. Guinea pig prostate is a rich source of nerve growth factor. Nature. 1979; 279: 160-2.
15. Heracek J, Lukes M, Grill R, Kuncova J, Zachoval R, Zalesky M, et al. Endokrinní profil muže s lokalizovaným karcinomem prostaty ve vztahu k pT a Gleason skóre. [(Endocrine profile in men with localized prostate cancer related to pT and Gleason score.) (In Czech)] Czech Urol. 2002; 6: 68.
16. Hilz H, Graefen M, Noldus J, Hammerer P, Knabbe C, Huland E, et al. Advanced prostate cancer is associated with a decrease in serum luteinizing hormone. Eur Urol. 2000; 38: 243-9.
17. Ho S, Leav I, Merk F, Yu M, Kwan P, Ziar J. Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol-17β. Lab Invest. 1995; 73: 356-65.
18. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000; 163: 824-7.
19. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev. 2001; 23: 42-58.
20. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993; 2: 27-32.
21. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 2003; 12: 1410-6.
22. Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patiens treated with radical prostatectomy. Eur Urol. 2005; 47: 308-12.
23. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005; 173: 1935-7.
24. Johnson MP, Thompson SA, Lubaroff DM. Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines. J Urol. 1985; 133: 1112-20.
25. Lau KM, Leav I, Ho SM. Rat estrogen receptor-α and -β, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology. 1998; 139: 424-7.
26. Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol. 1999; 154: 863-70.
27. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996; 88: 166.
28. Lukes M, Urban M, Zalesky M, Zachoval R, Heracek J, Zdarsky E. Prostate-Specific Antigen: Current Status. Folia Biol (Praha). 2001; 45: 41-9.
29. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling CH, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003; 169: 1670-5.
30. Montironi R, van der Kwast T, Boccon-Gibod L, Bono AV, Boccon-Gibod L. Handling and patology reporting of radical prostatectomy specimens. Eur Urol. 2003; 44: 626-36.
31. McPherson SJ, Wang H, Jones ME, Pedersen J, Ilismaa PT, Wreford N, et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology. 2001; 142: 2458-67.
32. Naslund MJ, Coffey DS. The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. J Urol. 1986; 136: 1136-40.
33. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest. 1997; 99: 618-27.
34. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2257-60.
35. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1262-9.
36. Porter AT, Ben-Josef E. Humoral mechanism in prostate cancer: A role for FSH. Urol Oncol. 2001; 6: 131-8.
37. Precioso D, Denis JL, Klocker H, Sciarra A, Reis M, Naber K, et al. Estrogens and aspects of prostate disease. Int J Urol. 2007; 14: 1-16.
38. Prins GS. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology. 1992; 130: 2401-12.
39. Prins GS, Birch L. The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. Endocrinology. 1995; 136: 1303-14.
40. Pylkkanen L, Makela S, Valve E, Harkonen P, Toikkanen S, Santti R. Prostatic dysplasia associated with increased expression of c-myc in neonatally estrogenized mice. J Urol. 1993; 149: 1593-1601.
41. Sastry BVR, Janson VE, Owens LK, Tayeb OS. Enkephalin - and substance P-like immunoreactives of mammalian sperm and accessory sex glands. Biochem Pharmacol. 1982; 31: 3519-22.
42. Sibley PE, Harper ME, Peeling WB, Griffiths K. Growth hormone and prostatic tumours: localization using a monoclonal human growth hormone antibody. J Endocrinol. 1984; 103: 311-5.
43. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours, 6th Edition. Wiley; 2002.
44. Srigley JR, Amin MB, Bostwick DG, Grignon DJ, Hammond EH. Updated protocol for the examination of specimen from patients with carcinomas of the prostate gland. Arch Pathol Lab Med. 2000; 124: 1034-9.
45. Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004; 108: 418-24,
46. Stattin P, Rinaldi S, Stenman U, Riboli E, Hallmans G, Bergh A, et al. Plasma prolactin and prostate cancer risk: A prospective study. Int J Cancer. 2001; 92: 463-5.
47. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005; 176: 2178-80.
48. True LD. Surgical pathology examination of the prostate gland. Practice survey by American society of clinical pathologists. Am J Clin Pathol. 1994; 102: 572-9.
49. Van Coppenolle F, Skryma R, Ouadid-Ahidouch H, Slomianny C, Roudbaraki M, Delcourt P, et al. Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation. Biochem J. 2004; 377: 569-78.
50. Van Coppenolle F, Le Bourhis X, Carpentier F, Delaby G, Cousse H, Raynaud JP, et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate. 2000; 43: 49-58.
51. Van Coppenolle F, Slomianny C, Carpentier F, Le Bourhis X, Ahidouch A, Croix D, et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am JPhysiol Endocrinol Metab. 2001; 280: 120-9.
52. Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male. 2002; 5: 170-6.
53. vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci. 1997; 94: 2056-61.
54. Wennbo H, Kindblom J, Isaksson OG, Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology. 1997; 138: 4410-5.